Core Insights - ALK presented significant advancements in anaphylaxis and pediatric allergy at the EAACI 2025 congress, highlighting innovations in treatment options and clinical evidence [1][4] Group 1: Innovations in Anaphylaxis Treatment - The EURneffy nasal adrenaline spray was introduced as a new treatment for anaphylaxis, supported by real-world data demonstrating its effectiveness in acute cases [2] - The nasal spray's pharmacological response is comparable to that of intramuscular adrenaline injections in patients with allergic rhinitis [2] Group 2: Immunotherapy Developments for Children - ALK showcased clinical evidence for sublingual allergy immunotherapy tablets aimed at children with respiratory allergies, indicating a transformative potential for allergy care [3] - Real-life data supports the long-term benefits of allergy immunotherapy in managing both upper and lower airway diseases in children [3] - Preliminary findings from the ALLIANCE clinical trial suggest that the peanut SLIT-tablet may be a well-tolerated treatment option for children with peanut allergies [3]